SG11202112043PA - Combination therapies comprising apremilast and tyk2 inhibitors - Google Patents
Combination therapies comprising apremilast and tyk2 inhibitorsInfo
- Publication number
- SG11202112043PA SG11202112043PA SG11202112043PA SG11202112043PA SG11202112043PA SG 11202112043P A SG11202112043P A SG 11202112043PA SG 11202112043P A SG11202112043P A SG 11202112043PA SG 11202112043P A SG11202112043P A SG 11202112043PA SG 11202112043P A SG11202112043P A SG 11202112043PA
- Authority
- SG
- Singapore
- Prior art keywords
- apremilast
- combination therapies
- tyk2 inhibitors
- tyk2
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/029772 WO2020222773A1 (en) | 2019-04-30 | 2019-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112043PA true SG11202112043PA (en) | 2021-11-29 |
Family
ID=66476870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112043PA SG11202112043PA (en) | 2019-04-30 | 2019-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
| SG11202112018YA SG11202112018YA (en) | 2019-04-30 | 2020-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112018YA SG11202112018YA (en) | 2019-04-30 | 2020-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3962475A1 (en) |
| JP (2) | JP2022537877A (en) |
| KR (2) | KR20220002488A (en) |
| CN (2) | CN114269336A (en) |
| AU (2) | AU2019443366A1 (en) |
| BR (2) | BR112021021809A2 (en) |
| CA (2) | CA3138473A1 (en) |
| CL (1) | CL2021002847A1 (en) |
| CO (2) | CO2021015622A2 (en) |
| IL (2) | IL287665A (en) |
| MA (1) | MA55799A (en) |
| MX (2) | MX2021013317A (en) |
| SG (2) | SG11202112043PA (en) |
| WO (2) | WO2020222773A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3138473A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| BR112023016590A2 (en) | 2021-02-19 | 2023-11-14 | Sudo Biosciences Ltd | TYK2 INHIBITORS AND THEIR USES |
| AU2022350509A1 (en) * | 2021-09-23 | 2024-04-04 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| TW201040162A (en) * | 2009-05-06 | 2010-11-16 | Portola Pharm Inc | Inhibitors of JAK |
| EP2638018A1 (en) | 2010-11-09 | 2013-09-18 | Cellzome Limited | Pyridine compounds and aza analogues thereof as tyk2 inhibitors |
| CA2834355A1 (en) * | 2011-04-28 | 2012-11-01 | Celgene Corporation | Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases |
| SI2797581T1 (en) * | 2011-12-27 | 2020-08-31 | Amgen (Europe) GmbH | Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione |
| KR20140108594A (en) | 2012-01-10 | 2014-09-11 | 에프. 호프만-라 로슈 아게 | Pyridazine amide compounds and their use as syk inhibitors |
| JPWO2013146963A1 (en) | 2012-03-28 | 2015-12-14 | 武田薬品工業株式会社 | Heterocyclic compounds |
| JP6197031B2 (en) | 2012-05-24 | 2017-09-13 | セルゾーム リミティッド | Heterocyclyl pyrimidine analogs as TYK2 inhibitors |
| EP2917186B1 (en) | 2012-11-08 | 2017-10-18 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn |
| MY194668A (en) | 2012-11-08 | 2022-12-12 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses |
| CN105050624A (en) * | 2013-03-14 | 2015-11-11 | 细胞基因公司 | Treatment of psoriatic arthritis using apremilast |
| US20160159773A1 (en) | 2013-07-30 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR102191084B1 (en) | 2013-09-03 | 2020-12-15 | 사름 리미티드 | Pharmaceutical compounds |
| TWI582077B (en) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses |
| JP6458038B2 (en) | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and / or IFNα responses |
| WO2015091584A1 (en) | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
| WO2015123453A1 (en) | 2014-02-14 | 2015-08-20 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as jak inhibitors |
| JP6526065B2 (en) | 2014-02-28 | 2019-06-05 | ニンバス ラクシュミ， インコーポレイテッド | TYK2 inhibitors and uses thereof |
| ES2749433T3 (en) * | 2014-06-23 | 2020-03-20 | Celgene Corp | Apremilast for the treatment of liver disease or abnormal liver function |
| EP3188745A1 (en) * | 2014-08-15 | 2017-07-12 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| NO2721710T3 (en) | 2014-08-21 | 2018-03-31 | ||
| WO2016047678A1 (en) | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | Heterocyclic compound |
| ES2930585T3 (en) | 2015-02-27 | 2022-12-19 | Nimbus Lakshmi Inc | TYK2 inhibitors and uses thereof |
| JP6802263B2 (en) | 2015-09-02 | 2020-12-16 | ニンバス ラクシュミ， インコーポレイテッド | TYK2 inhibitor and its use |
| RU2718902C2 (en) | 2016-02-24 | 2020-04-15 | Пфайзер Инк. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors |
| US10836770B2 (en) | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
| CA3039202A1 (en) | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CN110114357B (en) | 2016-10-28 | 2022-05-31 | 百时美施贵宝公司 | Hetero-bicyclic compounds useful as modulators of IL-12, IL-23, and/or IFN alpha response |
| JP7012082B2 (en) | 2016-11-17 | 2022-01-27 | ブリストル－マイヤーズ スクイブ カンパニー | Imidazopyridazine regulator of IL-12, IL-23 and / or IFN-alpha |
| GB2562702B (en) | 2017-03-06 | 2022-05-18 | Linear Shaped Ltd | Frame and linear shaped charge |
| EP4338802A2 (en) * | 2017-03-08 | 2024-03-20 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| CA3138473A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
-
2019
- 2019-04-30 CA CA3138473A patent/CA3138473A1/en active Pending
- 2019-04-30 JP JP2021564469A patent/JP2022537877A/en not_active Abandoned
- 2019-04-30 KR KR1020217038511A patent/KR20220002488A/en unknown
- 2019-04-30 CN CN201980097711.6A patent/CN114269336A/en active Pending
- 2019-04-30 EP EP19723291.1A patent/EP3962475A1/en active Pending
- 2019-04-30 AU AU2019443366A patent/AU2019443366A1/en not_active Abandoned
- 2019-04-30 SG SG11202112043PA patent/SG11202112043PA/en unknown
- 2019-04-30 MX MX2021013317A patent/MX2021013317A/en unknown
- 2019-04-30 BR BR112021021809A patent/BR112021021809A2/en unknown
- 2019-04-30 WO PCT/US2019/029772 patent/WO2020222773A1/en unknown
- 2019-04-30 IL IL287665A patent/IL287665A/en unknown
-
2020
- 2020-04-30 EP EP20725978.9A patent/EP3962476A1/en active Pending
- 2020-04-30 BR BR112021021826A patent/BR112021021826A8/en unknown
- 2020-04-30 JP JP2021564471A patent/JP7453251B2/en active Active
- 2020-04-30 CN CN202080046457.XA patent/CN114206333A/en active Pending
- 2020-04-30 AU AU2020266143A patent/AU2020266143A1/en active Pending
- 2020-04-30 SG SG11202112018YA patent/SG11202112018YA/en unknown
- 2020-04-30 WO PCT/US2020/030608 patent/WO2020223431A1/en unknown
- 2020-04-30 CA CA3138686A patent/CA3138686A1/en active Pending
- 2020-04-30 MA MA055799A patent/MA55799A/en unknown
- 2020-04-30 MX MX2021013318A patent/MX2021013318A/en unknown
- 2020-04-30 KR KR1020217038512A patent/KR20220002489A/en unknown
-
2021
- 2021-10-28 IL IL287670A patent/IL287670A/en unknown
- 2021-10-29 CL CL2021002847A patent/CL2021002847A1/en unknown
- 2021-11-22 CO CONC2021/0015622A patent/CO2021015622A2/en unknown
- 2021-11-22 CO CONC2021/0015614A patent/CO2021015614A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202112018YA (en) | 2021-11-29 |
| JP2022537877A (en) | 2022-08-31 |
| IL287670A (en) | 2021-12-01 |
| AU2020266143A1 (en) | 2021-12-02 |
| IL287665A (en) | 2022-07-01 |
| CA3138686A1 (en) | 2020-11-05 |
| JP7453251B2 (en) | 2024-03-19 |
| BR112021021809A2 (en) | 2022-01-04 |
| CN114269336A (en) | 2022-04-01 |
| JP2022537878A (en) | 2022-08-31 |
| MX2021013317A (en) | 2022-01-18 |
| CN114206333A (en) | 2022-03-18 |
| CO2021015622A2 (en) | 2022-02-28 |
| WO2020222773A1 (en) | 2020-11-05 |
| KR20220002488A (en) | 2022-01-06 |
| EP3962475A1 (en) | 2022-03-09 |
| AU2019443366A1 (en) | 2021-12-02 |
| MA55799A (en) | 2022-03-09 |
| CO2021015614A2 (en) | 2021-12-10 |
| EP3962476A1 (en) | 2022-03-09 |
| BR112021021826A8 (en) | 2022-06-21 |
| KR20220002489A (en) | 2022-01-06 |
| CL2021002847A1 (en) | 2022-07-22 |
| WO2020223431A1 (en) | 2020-11-05 |
| BR112021021826A2 (en) | 2022-01-04 |
| CA3138473A1 (en) | 2020-11-05 |
| MX2021013318A (en) | 2022-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL289534A (en) | Parp1 inhibitors | |
| IL271999A (en) | Tyk2 inhibitors and uses thereof | |
| SG10201913933YA (en) | Table game management system and game management system | |
| IL287670A (en) | Combination therapies comprising apremilast and tyk2 inhibitors | |
| IL276147A (en) | Gcn2 inhibitors and uses thereof | |
| IL276095B1 (en) | Gcn2 inhibitors and uses thereof | |
| IL281348A (en) | Combination therapies | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL284799A (en) | Tyk2 inhibitors and uses thereof | |
| IL283409A (en) | Tyk2 inhibitors and uses thereof | |
| EP3592354A4 (en) | Combination therapy with glutaminase inhibitors | |
| IL258500A (en) | Combination therapy with glutaminase inhibitors and immuno-oncology agents | |
| IL291659A (en) | Combination therapies | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| SG11202102377YA (en) | Combination therapies | |
| EP4107157A4 (en) | Setd2 inhibitors and related methods and uses, including combination therapies | |
| IL292198A (en) | Tim-3 inhibitors and uses thereof | |
| ZA202212919B (en) | Transposition-based therapies | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| IL308868A (en) | Combination therapies with setd2 inhibitors | |
| EP3716991A4 (en) | Trpv6 inhibitors and combination therapies for treating cancers | |
| EP3703822A4 (en) | Conjoint therapy with glutaminase inhibitors | |
| IL283687A (en) | Usp19 inhibitors for use in therapy |